ABPI Financials 07/16/2014 12:01:11
Accentia Biopharmaceuticals, Inc.
Period Ending Sep 30, 2012 Sep 30, 2011 Sep 30, 2010
Total Revenue 4,054 3,956 5,356
Cost of Revenue 2,770 2,490 2,901
Gross Profit 1,285 1,466 2,455
Operating Expenses
Research and Development 5,236 2,231 1,304
Sales, General and Admin. 7,547 20,377 4,341
Non-Recurring Items 40 30 415
Other - - -
Operating Income (11,538) (21,172) (3,604)
Income From Continuing Operations
Add'l Income/Expense Items 7,019 13,438 (27,136)
Earnings Before Interest and Tax (10,135) (20,090) (31,791)
Interest Expense 7,908 8,093 16,660
Earnings Before Tax (18,044) (28,184) (48,451)
Income Tax - 5 3
Minority Interest (4,865) (4,100) (412)
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (12,428) (15,827) (46,992)
Non Recurring Events
Discontinued Operations 3,240 179 (807)
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (9,188) (15,648) (47,799)
Preferred Stock and Other Adjustments - - (2,333)
Net Income Applicable to Common Shareholders (4,322) (11,553) (50,131)